開発中の歯肉炎治療薬(2022年):ステージ、ターゲット、MoA、RoA、分子タイプ、キープレーヤー

【英語タイトル】Gingivitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Global Markets Directが出版した調査資料(GMDHC22367IDB)・商品コード:GMDHC22367IDB
・発行会社(調査会社):Global Markets Direct
・発行日:2022年10月
・ページ数:32
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥296,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥592,000見積依頼/購入/質問フォーム
Enterprisewide Price(複数事業所内共有可)USD6,000 ⇒換算¥888,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

Global Markets Direct社の本調査レポートでは、開発中の歯肉炎治療薬市場について調査・分析し、歯肉炎概要、治療薬開発、パイプライン概要、企業別のパイプライン、企業別の開発中製品、治療薬分析、標的別分析、作用機序別分析、投与経路別分析、分子タイプ別分析、治療薬開発に携わる企業など、以下の項目を掲載しております。本書ではAmyndas Pharmaceuticals LLC、Avicanna Inc、Pacgen Life Science Corpなどの企業情報が含まれています。
・歯肉炎-概要
・歯肉炎-治療薬開発
・パイプライン概要
・企業別のパイプライン
・企業別の開発中製品
・歯肉炎-治療薬分析
・標的別分析
・作用機序別分析
・投与経路別分析
・分子タイプ別分析
・歯肉炎-治療薬開発に携わる企業

Gingivitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Gingivitis – Drugs In Development, 2022, provides an overview of the Gingivitis (Mouth And Dental Disorders) pipeline landscape.

Gingivitis is an inflammation of the gums, usually caused by a bacterial infection. Symptoms include sensitive teeth, pus between teeth and gums, loose teeth, gums that are red, tender, or swollen. Risk factors include diabetes, smoking or chewing tobacco, broken fillings, compromised immunity, and genetic factors. Treatment includes antibiotics.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Gingivitis – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Gingivitis (Mouth And Dental Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gingivitis (Mouth And Dental Disorders) pipeline guide also reviews of key players involved in therapeutic development for Gingivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Discovery stages are 2 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 2 molecules, respectively.

Gingivitis (Mouth And Dental Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Gingivitis (Mouth And Dental Disorders).
– The pipeline guide reviews pipeline therapeutics for Gingivitis (Mouth And Dental Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Gingivitis (Mouth And Dental Disorders) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Gingivitis (Mouth And Dental Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Gingivitis (Mouth And Dental Disorders)

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Gingivitis (Mouth And Dental Disorders).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Gingivitis (Mouth And Dental Disorders) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

❖ レポートの目次 ❖

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Gingivitis – Overview
Gingivitis – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Gingivitis – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Gingivitis – Companies Involved in Therapeutics Development
Amyndas Pharmaceuticals LLC
Avicanna Inc
Pacgen Life Science Corp
Gingivitis – Drug Profiles
AMY-101 – Drug Profile
Product Description
Mechanism Of Action
BLXA-4ME – Drug Profile
Product Description
Mechanism Of Action
KSL-W – Drug Profile
Product Description
Mechanism Of Action
P-113 – Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Agonize CB1 and CB2 for Gingivitis – Drug Profile
Product Description
Mechanism Of Action
Gingivitis – Dormant Projects
Gingivitis – Product Development Milestones
Featured News & Press Releases
Mar 09, 2021: Amyndas announces positive top-line phase 2 results for investigational AMY-101 in adults with periodontal inflammation and gingivitis
Aug 26, 2019: Amyndas Pharmaceuticals initiates phase 2a study of AMY-101 in adults with periodontal inflammation and gingivitis
Jan 24, 2017: Pacgen announces new markets for P113 products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Gingivitis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Gingivitis - Pipeline by Amyndas Pharmaceuticals LLC, 2022
Gingivitis - Pipeline by Avicanna Inc, 2022
Gingivitis - Pipeline by Pacgen Life Science Corp, 2022
Gingivitis - Dormant Projects, 2022

List of Figures
Number of Products under Development for Gingivitis, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

★調査レポート[開発中の歯肉炎治療薬(2022年):ステージ、ターゲット、MoA、RoA、分子タイプ、キープレーヤー] (コード:GMDHC22367IDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[開発中の歯肉炎治療薬(2022年):ステージ、ターゲット、MoA、RoA、分子タイプ、キープレーヤー]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆